Galectin reports Q2 net loss $9.2M; FDA agrees on Phase 3 design for belapectin

GALECTIN THERAPEUTICS INC

2026-Q2 EPS reported -$0.22

Net loss $9.2M ($0.14/share) vs $7.6M ($0.12/share) in Q2 2025; R&D $2.1M, G&A $1.8M.
FDA alignment on Phase 3 trial design for belapectin in MASH cirrhosis; protocol submission expected 3Q 2026.
Chairman Richard Uihlein converted $105.8M debt (principal $91M + interest $14.8M) into 34.4M shares, effective July 31, 2026.
Cash $13.2M at June 30, 2026; $10M line of credit available; cash runway through June 2027.
NAVIGATE trial data published in Hepatology and Gastro Hep Advances; EASL presentations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.